UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 26-1 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 26- ...

© 2023 Tonix Pharmaceuticals Holding Corp. © 2023 Tonix Pharmaceuticals Holding Corp. Tonix Pharmaceuticals is committed to improving population health by inventing and developing innovative therapies and vaccines, through broad in-house capabilities and creative collaborations, to help address important unmet needs. Investment Highlights IN-HOUSE CAPABILITIES FINANCIAL POSITION Candidates* Indication Status/Next Milestone TNX-13003 Cocaine Intoxication - FDA Breakthrough Designation Mid-Phase 2, Targeted 2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36019 TONIX PHARMACEUTICALS HOLDING CORP. (Exact name of registrant as specified in its charter) Nevada 26-1434750 (State or other jurisdiction of incorporation or organi ...

| --- | --- | --- | --- | --- | |-----------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | INVESTOR | | | | | | PRESENTATION NASDAQ: TNXP | | | | | | Version P0368 August 8, 2022 (Doc 1086) | | | | | © 2022 Tonix Pharmaceuticals Holding Corp. Cautionary Note on Forward-Looking Statements 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as de ...

| --- | --- | --- | --- | --- | --- | |-----------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | INVESTOR | | | | | | | PRESENTATION NASDAQ: TNXP | | | | | | | Version P0347 April 12, 2022 (Doc 0992) | | | | | | © 2022 Tonix Pharmaceuticals Holding Corp. | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | --- | --- | --- | |---------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | INVESTOR | | | | | | | PRESENTATION NASDAQ: TNXP | | | | | | | Version P0322 September 27, 2021 (Doc 0903) | | | | | | © 2021 Tonix Pharmaceuticals Holding Corp. CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS 2 Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations o ...

1 Investor Presentation NASDAQ:TNXP P H A R M A C E U T I C A L S September 2021 Version P0318 9-7-2021 (Doc 0892) © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such a ...

1 Investor Presentation NASDAQ:TNXP May 2021 Version P0295 5-12-2021 (Doc 0833) © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecas ...

1 Investor Presentation NASDAQ:TNXP April 2021 Version P0286 4-06-2021 (Doc 0815) © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward-Looking Statements Certain statements in this presentation regarding strategic plans, expectations and objectives for future operations or results are "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forec ...